Related Experiment Video
Updated: Jan 10, 2026
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
Plasma interferon predicts pulmonary hypertension severity and outcome
Zhanping Liang1,2, Yun Li1, Shuying Jia2
1Center for Translational Neurodegeneration and Regenerative Therapy, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, China.
Background:
Pulmonary hypertension (PH) is a complex and progressive disease characterized by elevated pulmonary vascular resistance. Inflammation plays an important role in the pathogenesis of PH. Interferons (IFNs) are key immune cytokines that regulate cellular responses to various stimuli. This study aimed to investigate the association between IFN levels and the risk and prognosis of PH.
Methods:
A cohort of 875 PH patients and 182 matched controls were included in this study. Logistic regression models and receiver operating characteristic (ROC) curves were applied to evaluate the association between IFN levels and PH risk. Correlations between variables were assessed using Spearman's rank correlation coefficient (r ). Cox proportional hazards regression and Kaplan-Meier survival curves were used to assess the prognostic value of IFNs levels. The predictive performance of prognostic models was assessed using ROC analysis and decision curve analysis and a nomogram was constructed to estimate individual overall survival probabilities.
Results:
Both IFN-α and IFN-γ levels were significantly elevated in PH patients compared with controls (P < 0.05 for both), with IFN-α showing stronger predictive value across multiple PH subgroups (P < 0.05 for all), particularly in patients with Group 4 PH and idiopathic pulmonary arterial hypertension (IPAH). In Cox regression models, IFN-α was significantly associated with lower survival in PH patients (HR: 1.120, 95% CI: 1.001-1.253, P = 0.048). Kaplan-Meier analysis demonstrated that patients with IFN-α > 2.131 pg/mL had significantly lower 5-year cumulative survival rate of 60.1%, compared with 81.2% for those with IFN-α ≤ 2.131 pg/mL (Log Rank P < 0.001). A prognostic model combining IFN-α with traditional clinical markers, such as WHO-FC, 6-MWD, and NT-proBNP, improved predictive accuracy, with IFN-α contributing additional clinical net benefit in risk stratification.
Conclusions:
These findings suggest that plasma IFN-α may serve as a valuable biomarker for both predicting PH risk and assessing prognosis.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care